Introduction
============

Thyroid nodules are one of the most common thyroid disorders. Ultrasound-guided fine needle aspiration (US-FNA) has been accepted as the gold standard for the differential diagnosis of thyroid nodules ([@b1-mco-0-0-1246]). However, there are certain limitations of US-FNA, including indeterminate results, which range in frequency from 10--33% ([@b2-mco-0-0-1246],[@b3-mco-0-0-1246]). The recommended clinical management for indeterminate aspirates is repeated US-FNA. However, a repeated US-FNA still has 38--48% indeterminate rate ([@b4-mco-0-0-1246],[@b5-mco-0-0-1246]). Otherwise, diagnostic surgery may be performed, which eventually will increase medical costs and suffering of patients ([@b1-mco-0-0-1246]). Ultrasound-guided core needle biopsy (US-CNB) presents a useful alternative method to obtain tissue from thyroid nodules for diagnosis. Previous studies have demonstrated that US-CNB was a useful alternative for the management of thyroid nodules with indeterminate FNA results ([@b4-mco-0-0-1246],[@b6-mco-0-0-1246]). However, US-CNB is not commonly used in the routine evaluation of thyroid nodules as a first-line method, and the major reason may be that US-CNB is proposed to increase the risk of bleeding and discomfort of patients ([@b7-mco-0-0-1246],[@b8-mco-0-0-1246]).

The purpose of the current meta-analysis was to evaluate US-CNB in the diagnosis of the thyroid nodules with suspicious US findings.

Data collection methods
=======================

### Literature search

Literature databases consisted of the Cochrane Library, Medline, Embase, Scopus and Google Scholar. The search terms used were core needle biopsy/coarse needle biopsy/core biopsy/CNB; thyroid nodules; thyroid cancer; head and neck tumors; neck masses. Articles were selected with publication dates up to July 29, 2015.

### Eligibility

Initially, the titles and abstracts of studies were independently reviewed for eligibility by two investigators. Discrepancies were resolved by a third evaluator or by consensus following a re-evaluation. There were no restrictions on study design, language or time period. The initial screening process produced a set of potentially eligible studies. Full reprints of all these potential studies were obtained and subjected to a more rigorous screen to produce a final set of eligible studies. Prospective and retrospective observational studies were considered eligible if they contained accuracy data for the diagnosis of thyroid nodules.

### Inclusion and exclusion criteria

Studies were finally included if they contained extractable data on the diagnosis of thyroid nodules. The main exclusion criteria were: i) articles not within the field of interest in this review, ii) nodules had selection bias, iii) diagnostic values such as sensitivity and specificity for malignancy were not studied with respect to thyroid nodules and iv) US-FNA has been performed but the outcomes were indeterminate or failed.

### Quality assessment

Quality appraisals of retrieved full-text articles were graded independently by two investigators for quality and applicability according to the Quality Assessment Tool for Diagnostic Accuracy Studies-2 (QUADAS-2) method. This widely used tool consisted of 11 items: Representative spectrum (item 1), reference standard (item 2), acceptable delay between tests (item 3), partial verification bias (item 4), differential verification bias (item 5), incorporation bias (item 6), reference standard results blinded (item 7), index text results blinded (item 8), relevant clinical information (item 9), uninterpretable results reported (item 10) and withdrawals explained (item 11). Disagreements were resolved by a third evaluator or by consensus following a re-evaluation of the references.

### Outcome analysis

The primary outcomes were the number of nodules that were true positive (TP), true negative (TN), false positive (FP) or false negative (FN). Subsequently, sensitivity, specificity, positive likelihood ratio (LR), negative LR, diagnostic odds ratio (DOR) and the area under the summery receiver operating characteristic curve (AUC) were evaluated. The biopsy results of US-CNB were grouped into six categories according to the Bethesda system ([@b9-mco-0-0-1246]), which was originally used for the analysis of US-FNA cytology: i) non-diagnostic, ii) benign, iii) atypical follicular lesion of undetermined significance (AUS/FLUS), iv) follicular neoplasm or suspected follicular lesion (FN/SFN), v) suspicious for cancer and vi) malignant lesions.

For malignant nodules, the final diagnoses were based on histological findings following surgical resection. For benign nodules, the final diagnoses were based on histological findings following surgical resection or a stable and uneventful follow-up. In the current meta-analysis, inconclusive results including non-diagnostic findings, AUS/FLUS and SFN/FN were excluded.

### Statistical analysis

The results of US-CNB were assessed using values for TP, TN, FP and FN. Diagnostic parameters were calculated as followed: Sensitivity = TP/(TP + FN), specificity = TN/(TN + FP), positivity LR = sensitivity/(1-specificity), negative LR = (1-sensivivity)/specificity and DOR = (TP/FP)/(FN/TN). Pooled estimates for sensitivity, specificity, positive LR, negative LR and DOR with the corresponding 95% confidence intervals (CIs) were used to examine the diagnostic ability of US-CNB for differentiating benign from malignant thyroid nodules. The pooled estimates were derived using the fixed-effects model (Mantel-Haenszel method) if significant heterogeneity was not present. In case of heterogeneity, the random-effects model (DerSimonian-Laird method) was applied. Summary receiver operating characteristic (SROC) curves were constructed using the Moses-Shapiro-Lit-tenberg (inverse variance) method. Heterogeneity was explored via the Cochran Q test, and a P-value of \<0.01 indicated the presence of heterogeneity. Inconsistency was calculated by I^2^ to describe the percentage of variability due to heterogeneity, rather than sampling errors. An I^2^ value \>50% was considered indicative of substantial heterogeneity ([@b10-mco-0-0-1246]). Data were analyzed using Review Manager software (RevMan version 5.3, Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and Meta-Disc software (version 1.4) ([@b11-mco-0-0-1246]). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Study retrieval

Initially, 1,274 studies were identified. Following title and abstract scrutiny, 1,245 irrelevant studies were removed. From the 29 obtained potentially eligible articles, 8 papers were finally included ([Fig. 1](#f1-mco-0-0-1246){ref-type="fig"}) ([@b7-mco-0-0-1246],[@b8-mco-0-0-1246],[@b12-mco-0-0-1246]--[@b17-mco-0-0-1246]) There was 1 prospective study and 7 retrospective studies, and the parameters of the investigations are provided in [Table I](#tI-mco-0-0-1246){ref-type="table"}.

### Study quality

A summary of the QUADAS-2 quality assessment is presented in [Fig. 2](#f2-mco-0-0-1246){ref-type="fig"}. Nodules with at least one of the following malignancy-suspicious US findings were subjected to US-CNB: Calcification, hypoechogenicity, irregular margin, vascularity, and taller than wide (item 1). The gold standard was surgical pathology (item 2). No studies specifically mentioned the time between US-CNB and histological evaluation, except for that by Paja *et al* ([@b14-mco-0-0-1246]), which clearly stated that the interval between US-CNB and surgery was less than 12 months in all cases (item 3). Although this may lead to timing bias, in the majority of institutions, the interval between US-CNB and histological evaluation was likely to be short. All cases were evaluated against a reference standard. The majority of studies were based only on histologically verified samples, which may lead to partial verification bias (item 4). In addition, 2 studies used histological confirmation and clinical follow-up as reference standards (item 5). The index test was independent of the reference test (item 6). It was usual practice for the reference standard to be evaluated with knowledge of the index test results (item 7), and the index test was always interpreted without knowledge of the reference standard (item 8), thus, there was potential for the knowledge of the US-CNB diagnosis to influence the histological diagnosis. The majority of the studies were retrospective, and clinical data were available at the time of diagnosis by the index test (item 9). Three studies included non-diagnostic findings, AUS/FLU and SFN/FN (item 10), and the withdrawals were explained (item 11).

### Diagnostic analysis

In the 8 studies included in this meta-analysis, there were a total of 5,370 nodules, including 618 indeterminate nodules. The rate of indeterminate results ranged from 0--17.8%, and the pooled rate of indeterminate results was 11.5%. In 5,370 nodules, 1,738 nodules were followed-up, but 117 of these nodules were indeterminate, so 1,621 nodules were finally included in this meta-analysis ([Table I](#tI-mco-0-0-1246){ref-type="table"}).

The compilations of sensitivity, specificity, accuracy and positive predictive value of US-CNB for thyroid cancer are displayed in [Table II](#tII-mco-0-0-1246){ref-type="table"}. The sensitivity for malignancy ranged from 0.69--1, the specificity for malignancy ranged from 0.35--1, and the accuracy ranged from 0.53--1. The random-effects model was used for determining the pooled diagnostic sensitivity, as homogeneity tests of sensitivity revealed that Q=57.43 (P\<0.01) and I^2^=87.8%. The pooled sensitivity for malignancy was 0.96 (95% CI=0.94--0.97) ([Fig. 3](#f3-mco-0-0-1246){ref-type="fig"}). Similarly, the random-effects model was used for determining the pooled diagnostic specificity, as homogeneity tests of sensitivity showed Q=107.35 (P\<0.01) and I^2^=93.5%. The pooled specificity was 0.96 (95% CI=0.94--0.97) ([Fig. 4](#f4-mco-0-0-1246){ref-type="fig"}).

The positive LR was 18.20 (95% CI=2.21--156.41; Q=284.00; P\<0.01) and I^2^=97.5% ([Fig. 5](#f5-mco-0-0-1246){ref-type="fig"}). The negative LR was 0.08 (95% CI=0.02--0.27; Q=87.41; P\<0.01) and I^2^=92.0% ([Fig. 6](#f6-mco-0-0-1246){ref-type="fig"}). The DOR was 250.60 (95% CI=19.11--3286.76) (Q=120.83; P\<0.01) and I^2^=94.2% ([Fig. 7](#f7-mco-0-0-1246){ref-type="fig"}). The AUC was 0.979 (standard error=0.018) ([Fig. 8](#f8-mco-0-0-1246){ref-type="fig"}).

### Complications of US-CNB

In total, 73 hematomas and 1 recurrent nerve lesion were reported from a total of 5,370 nodules ([Table III](#tIII-mco-0-0-1246){ref-type="table"}). The overall risk of the hematoma was 1.3%.

Discussion
==========

Thyroid nodules are very common, and their prevalence has dramatically increased in recent years ([@b18-mco-0-0-1246],[@b19-mco-0-0-1246]). Although the risk of malignancy is fairly low, it must be considered ([@b1-mco-0-0-1246],[@b20-mco-0-0-1246],[@b21-mco-0-0-1246]). The early detection and distinction between benign or malignant thyroid nodules is particularly important to guide clinical treatment and select operative methods. At present, ultrasound is widely used in the initial differentiation. Several ultrasound features, such as irregular, taller than wide dimensions, microcalcifications and hypoechogenicity have been considered to be malignant signs ([@b22-mco-0-0-1246]). However, none of these characteristics appears sufficient to diagnose malignancy individually, and in numerous cases ambiguous features result in uncertain ultrasonic diagnosis. Therefore, US-FNA and cytopathology is now considered as the gold standard to identify thyroid nodules with suspiciously concerning clinical and/or sonographic features. Nevertheless, US-FNA has been limited by the rate of indeterminate results (including non-diagnostic AUS/FLUS and FN/SFN findings) to a certain extent. It has been reported that indeterminate rate of the US-FNA was between 10.9--33% ([@b2-mco-0-0-1246],[@b3-mco-0-0-1246],[@b23-mco-0-0-1246]--[@b25-mco-0-0-1246]). The malignancy rate of the surgical follow-up in AUS/FLUS ranged from 6--48% ([@b26-mco-0-0-1246]) and in FN/SFN between 10 and 30% ([@b27-mco-0-0-1246],[@b28-mco-0-0-1246]).

US-CNB has been revealed to be useful in combination with US-FNA or following insufficient, non-diagnostic or atypia of uncertain significance results in US-FNA ([@b5-mco-0-0-1246],[@b6-mco-0-0-1246],[@b29-mco-0-0-1246],[@b30-mco-0-0-1246]). However, few reports have been conducted to evaluate the usefulness of US-CNB as a routine diagnostic procedure for thyroid nodules. In a prior meta-analysis, Li *et al* ([@b31-mco-0-0-1246]) evaluated US-FNA and US-CNB in diagnosing thyroid nodule malignancy. This recently published review included 5 studies and elucidated a US-FNA sensitivity of 68% and a specificity of 93% for detecting thyroid cancer, and US-CNB was able to detect thyroid malignancy with a sensitivity of 83% and a specificity of 94%. The number of studies included in the above meta-analysis was smaller than that in the current study. To the best of our knowledge, the present study is the only dedicated meta-analysis and literature review of US-CNB for thyroid nodules. The present meta-analysis included 1,621 nodules from 8 studies. The results revealed that US-CNB for thyroid nodules was a useful technique with high pooled sensitivity (96%) and high pooled specificity (96%), confirming that US-CNB was an effective method for identifying malignancy in thyroid nodules. With increased evidence inclusion in the current analysis, markedly higher diagnostic capabilities of US-CNB than the findings from Li *et al* ([@b31-mco-0-0-1246]) were identified.

Higher economical cost, concerns about potential complications, technical requirements and time consumption may limit the use of US-CNB. It may be considered that US-CNB has the potential to increase patient discomfort and enhance complications. However, prior investigations revealed that compared with US-FNA, US-CNB did not increase the patient discomfort significantly ([@b5-mco-0-0-1246]--[@b8-mco-0-0-1246],[@b15-mco-0-0-1246],[@b29-mco-0-0-1246],[@b30-mco-0-0-1246],[@b32-mco-0-0-1246]--[@b36-mco-0-0-1246]). In the present meta-analysis, the reported complications are compiled in [Table III](#tIII-mco-0-0-1246){ref-type="table"}. The most common was post-biopsy hematoma ([@b7-mco-0-0-1246],[@b8-mco-0-0-1246],[@b12-mco-0-0-1246]--[@b15-mco-0-0-1246]), but the majority of patients did not require treatment for this complication. Only one patient suffered from recurrent nerve damage following a direct puncture of the nerve, which finally caused permanent dysphonia. However, this type of complication was also reported with US-FNA ([@b37-mco-0-0-1246]). Furthermore, Bergeron *et al* ([@b38-mco-0-0-1246]) reported an iatrogenic arteriovenous fistula formation following US-CNB, eventually causing tinnitus. In order to minimize such critical complications, US-CNB must be performed with experienced radiologists with dedicated training, who are familiar with the radiological features of important anatomical structures in the cervical region. Compared with US-FNA, US-CNB appears to depend more on the experience and skill of the operator and cytology interpretation. In addition, the cost of US-CNB requires consideration. Trimboli *et al* ([@b39-mco-0-0-1246]) reported that US-CNB cost 1,000 Euros per patient, and this price was much higher than the cost of US-FNA (about 150 Euros). Although US-CNB is more expensive, considering the collective cost of repeat US-FNA and diagnostic surgery, and the associated patient suffering due to surgery, the cost of US-CNB is reasonable.

The current meta-analysis had several potential sources of bias and limitations. Firstly, 7 of the 8 included studies were retrospective. Retrospective studies frequently tend to include post-surgical cases with positive results, and in this way positive rate will be much higher than the negative rate. Three retrospective and one prospective study included in this meta-analysis avoided this problem in that they included all cases within a specified period of time and used clinical follow-up to verify cases with a negative US-CNB. Second, the heterogeneity of the included studies was also a matter of concern. The degree of heterogeneity in the present study was relatively high. It was considered that variance across the included studies was attributed to heterogeneity. The potential confounding variances included, for example: The choice of the nodules, the shape and size of the nodules and the experience of the operator. In addition, baseline differences among the patients in the included studies and in the study qualities may also contribute to heterogeneity. Third, publication bias was another concern, as studies that reported significance were more likely to be published than those reporting non-significant results. Fourth, although the current study provided evidence suggesting that US-CNB had high sensitivity and specificity for the detection of malignancy nodules in thyroid, it was also based on a relatively small number of studies.

In conclusion, the present meta-analysis suggests that US-CNB is a safe, reliable, and accurate method to assess thyroid nodules. It has high sensitivity and specificity, and has low risk of complications for the diagnosis of malignant thyroid nodules, which may avoid repeat US-FNA and diagnostic surgery.
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###### 

Basic characteristics of studies included in this meta-analysis

  First author (year)   Design          No. of nodules   Inadequate samples (%)   No. of cases including follow-up   Finally included   Male/female   Age, years (range)   (Refs.)
  --------------------- --------------- ---------------- ------------------------ ---------------------------------- ------------------ ------------- -------------------- -----------------------
  Chen (2015)           Retrospective   365              63 (17.3)                89                                 89                 286/79        58 (14--85)          ([@b12-mco-0-0-1246])
  Harvey (2005)         Retrospective   79               10 (12.7)                69                                 69                 NK            NK                   ([@b13-mco-0-0-1246])
  Karstrup (2001)       Retrospective   77               9 (11.7)                 41                                 36                 13/64         51 (33--81)          ([@b7-mco-0-0-1246])
  Paja (2015)           Retrospective   3,517            364 (10.3)               676                                522                NK            NK                   ([@b14-mco-0-0-1246])
  Renshaw (2007)        Retrospective   377              67 (17.8)                62                                 55                 76/301        52 (14--86)          ([@b8-mco-0-0-1246])
  Sung (2012)           Retrospective   555              82 (14.8)                555                                473                85/453        44.32±11.86          ([@b15-mco-0-0-1246])
  Trimboli (2014)       Prospective     31               1 (3.2)                  31                                 30                 NK            NK                   ([@b16-mco-0-0-1246])
  Zhang (2014)          Retrospective   369              22 (6.0)                 369                                347                101/254       47.7±11.8 (14--78)   ([@b17-mco-0-0-1246])

NK, not known.

###### 

Performance of the included studies.

  First author (year)   TP    FP   FN   TN    Total   Sensitivity (%)   Specificity (%)   Accuracy (%)   Positive predictive value (%)   Final diagnosis                             (Refs.)
  --------------------- ----- ---- ---- ----- ------- ----------------- ----------------- -------------- ------------------------------- ------------------------------------------- -----------------------
  Chen (2015)           26    4    6    53    89      81.3              93                88.8           86.7                            Surgical resection                          ([@b12-mco-0-0-1246])
  Harvey (2005)         6     7    0    56    69      100               88.9              89.9           46.2                            Surgical resection and clinical follow-up   ([@b13-mco-0-0-1246])
  Karstrup (2001)       14    1    4    17    36      77.8              94.4              86.1           93.3                            Surgical resection                          ([@b7-mco-0-0-1246])
  Paja (2015)           145   3    8    366   522     94.8              99.2              97.9           98                              Surgical resection                          ([@b14-mco-0-0-1246])
  Renshaw (2007)        20    17   9    9     55      69.0              34.6              52.7           54.1                            Surgical resection                          ([@b8-mco-0-0-1246])
  Sung (2012)           276   2    2    193   473     99.3              99.0              99.2           99.3                            Surgical resection and clinical follow-up   ([@b15-mco-0-0-1246])
  Trimboli (2014)       24    0    0    6     30      100.0             100.0             100.0          100.0                           Surgical resection                          ([@b16-mco-0-0-1246])
  Zhang (2014)          211   2    5    129   347     97.7              98.5              98.0           99.1                            Surgical resection and clinical follow-up   ([@b17-mco-0-0-1246])

TP, true positive; FP, false positive; FN, false negative; TN, true negative.

###### 

Complications in the included studies

  First author (year)   Needle gauge passes   Total   Complications                                                                     (Refs.)
  --------------------- --------------------- ------- --------------------------------------------------------------------------------- -----------------------
  Chen (2015)           NK                    365     1 hematoma                                                                        ([@b12-mco-0-0-1246])
  Harvey (2005)         18                    79      1 hematoma                                                                        ([@b13-mco-0-0-1246])
  Karstrup (2001)       18                    77      3 hematomas                                                                       ([@b7-mco-0-0-1246])
  Paja (2015)           18                    3,517   56 hematomas, 1 recurrent nerve lesion following a direct puncture of the nerve   ([@b14-mco-0-0-1246])
  Renshaw (2007)        18, 20, 21            377     1 hematoma                                                                        ([@b8-mco-0-0-1246])
  Sung (2012)           18                    555     11 hematomas^[a](#tfn3-mco-0-0-1246){ref-type="table-fn"}^                        ([@b15-mco-0-0-1246])
  Trimboli (2014)       21                    31      None                                                                              ([@b16-mco-0-0-1246])
  Zhang (2014)          18                    369     None                                                                              ([@b17-mco-0-0-1246])

Included ultrasound-guided fine needle aspiration and ultrasound-guided core needle biopsy NK, not known.
